Table 1 Ongoing and planned clinical trials of thiamine, ascorbic acid, and corticosteroids, in sepsis
Trial name | Trial identifier | Country | Population | Primary outcome |
|---|---|---|---|---|
Ascorbic acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial | NCT03389555 | USA | Septic shock | Change in SOFA score |
Vitamin C, Thiamine and Steroids in Sepsis (VICTAS) | NCT03509350 | USA | Sepsis with acute cardiovascular or respiratory compromise | Vasopressor- and ventilator-free days |
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock (HYVCTTSSS) | NCT03258684 | China | Sepsis or septic shock (Sepsis-3 Criteria) | Hospital mortality |
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock | NCT03335124 | Slovenia | Severe sepsis or septic shock | Hospital mortality |
Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis (ORANGES) | NCT03422159 | USA | Sepsis or septic shock | Hospital mortality |
The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial (VITAMINS) | NCT03333278 | Australia and New Zealand | Septic shock | Vasopressor-free days |
Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock (HYVITS) | NCT03380507 | Qatar | Septic shock | Hospital mortality |
Steroids, Thiamine, and Vitamin C in Septic Shock (STACSS) | CTRI/2018/04/013384 | India | Septic shock | Shock reversal |
Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock | NCT03540628 | USA | Septic shock | Mortality (as compared to the study by Marik et al. [6]) |